Doravirine Dose Optimisation in Pregnancy

This study is investigating the best dose of doravirine — an HIV medication — during pregnancy and breastfeeding. HIV drug levels in the body change during pregnancy, and the standard dose may not be effective enough. The study aims to find the optimal dose to protect both the mother and the baby from HIV. **You may be eligible if...** - You are an HIV-positive woman, 18 or older - You are pregnant (between 12 and 26 weeks of gestation) and starting combination HIV treatment for the first time in at least 6 months - You plan to breastfeed after delivery - You are able and willing to follow study procedures **You may NOT be eligible if...** - You have received HIV treatment in the past 6 months - You have chronic hepatitis B with liver inflammation - You have significant liver enzyme abnormalities - You have previously had a failed HIV treatment regimen using a similar class of drugs (NNRTIs) - You have had an allergic reaction to any HIV medication - You are taking medications that interact with doravirine (such as rifampicin or certain anti-epileptic drugs) - You have severe depression or are considered at risk for suicide Talk to your doctor to see if this trial is right for you.